Phase II Results for Pembrolizumab Monotherapy in Metastatic TNBC

June 20, 2017
Sylvia Adams, MD

Sylvia Adams, MD, associate professor, Department of Medicine, NYU Langone Medical Center, discusses phase II results from cohort A of the KEYNOTE-086 trial, which explored pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer.